Add to ORKGA randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantatio
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Recently a novel subgroup of bronchiolitis obliterans syndrome (BOS) has been described in patients ...
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following...
Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients ...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: This review ...
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the leading cause of morbidity/mortality in l...
Introduction Azithromycin stabilises and improves lung function forced expiratory volume in one seco...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
Prophylactic azithromycin treatment has been demonstrated to improve freedom from bronchiolitis obli...
Bronchiolitis obliterans syndrome (BOS) remains a major problem after lung transplantation. Azithrom...
BACKGROUND: Azithromycin may reverse or halt the decline of pulmonary function (FEV(1)) in bronchiol...
WINNING ABSTRACT: BOS is the most important cause of late mortality after LTx. Until 5 years ago, th...
Lung transplantation remains the only effective therapeutic option for well-selected patients with e...
OF OBJECTIVES: Bronchiolitis obliterans syndrome (BOS), the most common form of chronic lung allogra...
Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term survival...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Recently a novel subgroup of bronchiolitis obliterans syndrome (BOS) has been described in patients ...
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following...
Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients ...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: This review ...
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the leading cause of morbidity/mortality in l...
Introduction Azithromycin stabilises and improves lung function forced expiratory volume in one seco...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
Prophylactic azithromycin treatment has been demonstrated to improve freedom from bronchiolitis obli...
Bronchiolitis obliterans syndrome (BOS) remains a major problem after lung transplantation. Azithrom...
BACKGROUND: Azithromycin may reverse or halt the decline of pulmonary function (FEV(1)) in bronchiol...
WINNING ABSTRACT: BOS is the most important cause of late mortality after LTx. Until 5 years ago, th...
Lung transplantation remains the only effective therapeutic option for well-selected patients with e...
OF OBJECTIVES: Bronchiolitis obliterans syndrome (BOS), the most common form of chronic lung allogra...
Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term survival...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Recently a novel subgroup of bronchiolitis obliterans syndrome (BOS) has been described in patients ...
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following...